Product development(Formulation) officer

I am a precision-driven pharmaceutical and biomedical researcher with a multidisciplinary foundation in pharmacology, clinical pharmacy, industrial pharmacy, and biotechnology. I bring experience in both academic and industry environments, with a focus on quality-centric product development, dosage form innovation, neuropharmacology, and molecular research targeting chronic mental illnesses. I hold two master’s degrees: an MSc in Pharmacology and Clinical Pharmacy from East West University (2023), Bangladesh, and an MRes/MPhil in Biotechnology for Life Sciences from the University of Rijeka, Croatia (ongoing). In my previous review article titled "The Prospect of Stem Cells for HIV and Cancer Treatment," I explore the exciting potential of stem cells in treating previously incurable diseases. Stem cells are capable of differentiating into specialized functional cells, a property that holds promise for patients with HIV and cancer. Advances in cell engineering and genetic reprogramming have opened new avenues for stem cell therapies, such as the recent case where HIV patients received stem cell transplants, replacing their white blood cells with HIV-resistant versions. Despite these groundbreaking developments, only a few clinical successes have emerged so far, highlighting the challenges of translating stem cell research into practical treatments. The review presents a two-part approach: the first section provides foundational knowledge on stem cells, while the second focuses on the emerging opportunities and challenges in translating basic stem cell research into clinical applications for HIV and cancer. My research spans molecular mechanisms of psychiatric diseases, advanced formulation development, and clinical and molecular pharmacology. I excel in protein aggregation in major mental illness, with a particular focus on CRMP1 in schizophrenia. I use Drosophila melanogaster, rodent behavioral models, and human-derived cell lines (HEK293 and SH-SY5Y) to dissect neuropathological pathways and investigate potential therapeutic targets. My work combines molecular cloning, immunostaining, confocal microscopy, and protein-protein interaction assays to explore neuroinflammatory cascades and protein-protein aggregation patterns. In parallel, I have developed thermosensitive gels, gastroretentive dosage forms, and mucoadhesive delivery systems. I’ve also investigated antifungal, anti-inflammatory, and anti-ulcer drug formulations, gaining real-world pharmaceutical experience in product life cycle optimization, process validation, and post-marketing surveillance. I am deeply invested in formulation strategies that maximize bioavailability, patient compliance, and clinical utility. I have conducted epidemiological research on COVID-19 and its behavioral implications, offering public health insights into compliance, vaccination trends, and mental well-being. This added an interdisciplinary layer to my profile, connecting pharmacoepidemiology with community health research. I’ve led and participated in cross-border collaborative projects, including summer schools in the US and Europe that focus on pathophysiology, etiopathophysiology, prevention, treatment, diagnosis, cure, remedies, and translational neuroscience. I presented original research on CRMP1 aggregation at the 2024 NeuRi Congress and contributed to collaborative publications and thesis projects on stem cell therapy, protein misfolding, and CNS repair. My scientific writing portfolio includes literature reviews, thesis dissertations, grant proposals, and pre-marketed prototype formulation developments aligned with ICH and GLP standards, with experience in USFDA and EU project handling. I am well-versed in SPSS, GraphPad Prism, MS Excel, MedCalc, Statistica, and other relevant biostatistics tools. My long-term goal is to lead cutting-edge research on therapeutic strategies for chronic mental illness and neurodegeneration, integrating protein aggregation dynamics, cell therapy, and personalized medicine. I aim to create a clinical bridge between Drosophila and human biology using cell-based disease models to validate new targets. I aspire to develop neurotherapeutic interventions that translate laboratory innovation into meaningful patient outcomes. As I advance in my research career, I am actively seeking opportunities for collaboration, co-publication, and international research partnerships. I am particularly interested in biotech-academic consortia focused on CNS drug discovery, protein misfolding diseases, regenerative medicine, and psychiatric genomics. I believe science should be scalable, ethical, and culturally responsive. Through interdisciplinary synergy, I hope to contribute to impactful innovations that enhance both scientific understanding and global health outcomes.